Scarica l'app Stockscreener
432.83
1.48%
-6.51
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Teachers Retirement System of The State of Kentucky Invests $1.32 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
20 new Madrigal staff get stock options and 6,882 RSUs at $432 - Stock Titan
Aug Shorts: Will UnitedHealth Group Incorporated stock go up in YEARQuarterly Performance Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Risk Check: Can Madrigal Pharmaceuticals Inc weather a recessionWeekly Stock Analysis & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Segall Bryant & Hamill LLC Invests $10.32 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - simplywall.st
Madrigal Pharmaceuticals: How Noninvasive Data Is Powering a Smarter Clinical Strategy! - Smartkarma
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by TD Asset Management Inc - MarketBeat
Madrigal Revenue Beats Highlight Rezdiffra Momentum And Investor Trade Offs - simplywall.st
MDGL: Rezdiffra's growth accelerates with a broad pipeline and strong 2026 financial outlook - TradingView
Intech Investment Management LLC Lowers Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success - Finviz
Madrigal Pharmaceuticals EVP Dier sells $505k in shares By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals (NASDAQ:MDGL) CFO Mardi Dier Sells 1,183 Shares - MarketBeat
Madrigal Pharmaceuticals (MDGL) director sale notice: 1,183 shares after RSU vest - Stock Titan
MADRIGAL PHARMACEUTICALS EVP and CFO Sells Shares to Cover Tax Obligations - TradingView
Madrigal (MDGL) CFO has shares sold automatically for tax withholding - Stock Titan
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Exploring a 54% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Rafferty Asset Management LLC Lowers Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
JPMorgan Chase & Co. Reduces Stake in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
William Blair Investment Management LLC Has $188.88 Million Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Artisan Partners Limited Partnership Acquires 4,683 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Q4 earnings miss, MASH drug sales drive top line, stock down - MSN
MDGL SEC FilingsMadrigal Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
Fox Run Management L.L.C. Takes $1.06 Million Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Why Madrigal Pharmaceuticals (MDGL) Is Down 9.7% After Rezdiffra’s Near US$1 Billion Debut Year - Yahoo Finance
Exit Recap: Will Madrigal Pharmaceuticals Inc outperform during market ralliesEarnings Summary Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Madrigal: The Easiest Money May Have Been Made (NASDAQ:MDGL) - Seeking Alpha
Director exercises 2,500 Madrigal (MDGL) options at $7.36 - Stock Titan
Madrigal Pharmaceuticals Reports 2025 Financial Results - MyChesCo
Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference - The Manila Times
Madrigal to webcast TD Cowen health conference talk Mar. 3 - Stock Titan
Madrigal Grants Inducement Awards to Five Employees - MyChesCo
Madrigal (MDGL) Q4 2025 Earnings Call Transcript - The Globe and Mail
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra’s First Full Year Near US$1b In Sales - simplywall.st
Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook Reveals 53% Potential Upside In Biotechnology - DirectorsTalk Interviews
Vanguard Group Inc. Sells 65,227 Shares of Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal’s Rezdiffra Breakthrough Spurs MASH Pipeline Growth And Valuation Debate - Yahoo Finance
MASH Drugs Market to hit US$ 929.05 Million by 2033 | North America - openPR.com
Madrigal Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Bitget
Is now the right time to enter Madrigal Pharmaceuticals Inc.July 2025 Opening Moves & Safe Entry Momentum Tips - mfd.ru
MDGL: B of A Securities Maintains Neutral Rating, Lowers Price T - GuruFocus
Bank of America Issues Pessimistic Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2025 Earnings Call Transcript - Insider Monkey
Fiera Capital Corp Lowers Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi - Yahoo Finance
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus
Madrigal Pharma earnings missed by $1.97, revenue topped estimates - Investing.com Canada
Madrigal Eyes MASH Future As Rezdiffra Nears Blockbuster Revenue - Citeline News & Insights
Earnings call transcript: Madrigal Pharmaceuticals Q4 2025 misses EPS, stock dips - Investing.com India
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highlights: Record Sales and ... By GuruFocus - Investing.com Canada
Madrigal Pharmaceuticals Inc (MDGL) Q4 2025 Earnings Call Highli - GuruFocus
Madrigal Pharmaceuticals (NASDAQ:MDGL) Posts Quarterly Earnings Results, Misses Estimates By $2.61 EPS - MarketBeat
Madrigal Pharmaceuticals, Inc. reports strong Rezdiffra sales growth in Q4 2025; first full year of launch approaches $1 billion in net sales - AlphaStreet News
Madrigal Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Madrigal Pharmaceuticals (MDGL) Reports Strong Q4 2025 Performan - GuruFocus
Madrigal Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down After Earnings Miss - MarketBeat
Madrigal Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Madrigal Pharmaceuticals Stock Drops 11% Despite Reporting Narrower Loss In Q4 - Nasdaq
Sector Update: Health Care Stocks Flat to Lower Pre-Bell Thursday - marketscreener.com
1.24%
2.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):